Answer given by Mrs Reding on behalf of the Commission
Member States are competent for developing and implementing policies on drug prevention, treatment and harm reduction that work best in their socioeconomic and cultural contexts. The European Commission supports and complements Member States' action on drug-demand reduction, by promoting the development of effective and innovative approaches and the sharing of best-practice in this area through the EU financial programmes, the Drug Prevention and Information Programme(1) and the Public Health Programme(2).
The EU action on drugs is guided by the EU Drugs Strategy 2005‑2012(3), which identifies drug-demand reduction as one of the main pillars of EU drugs policy. The European Commission has commissioned an external evaluation of the implementation of the EU Drugs Strategy 2005‑2012, which was conducted by RAND Europe. The evaluation report, delivered in March 2012, highlights a number of achievements in the area of demand reduction. The Commission has sent the evaluation report to the ENVI and LIBE secretariats.
In October 2011, the Commission presented its communication ‘Towards a stronger European response to drugs’(4), announcing a number of initiatives that it will take over the next years to address the drugs problem. These include measures for EU minimum quality standards in prevention, treatment and harm reduction, to improve the quality of drug-related services across the EU.